ACCEL Lite: Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL-Cholesterol
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research - Un pódcast de American College of Cardiology - Martes
Categorías:
After a heart attack, levels of blood lipids such as low-density lipoprotein cholesterol (LDL-C) may influence the risk of further cardiovascular events. In this analysis, we determined that even when LDL-C levels are controlled with a statin, elevated levels of another blood lipid called lipoprotein(a) are associated with an increased risk of further cardiovascular events and a benefit of treatment with the PCSK9 inhibitors. In this interview, Gregory G. Schwartz, MD, PhD and Glenn A. Hirsch MD, MHS, FACC, with Lindsay Panah, MD, discuss Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients with Nominally Controlled LDL-Cholesterol.
